OncoMatch/Clinical Trials/NCT05000554
The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer
Is NCT05000554 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for gastric cancer.
To explore the safety and efficacy of local advanced stomach cancer patients receiving new complementary treatment of PD-1 monoantiotherapy before surgery
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Biomarker criteria
Required: PD-L1 (CD274) CPS≥1 (CPS≥1)
PD-L1+(CPS≥1)
Disease stage
Required: Stage CT3-4A
Clinical cT3-4a/N+M0 disease, confirmed by upper gastrointestinal endoscopy and abdominal computed tomography (CT) and laparoscopy
Prior therapy
Cannot have received: chemotherapy
No previous treatment with chemotherapy or radiation therapy for any tumors
Cannot have received: radiation therapy
No previous treatment with chemotherapy or radiation therapy for any tumors
Cannot have received: surgery
No previous surgery for the present disease
Lab requirements
Blood counts
White blood cell count≥3000/mm3 (2000/mm3) Platelet count≥10.0*104/mm3 (5.0*104/mm3)
Kidney function
Serum creatinine≤1.5 mg/dl
Liver function
Aspartate aminotransferase≤100 IU/l Alanine aminotransferase≤100 IU/l Total bilirubin≤2.0 mg/dl
Sufficient organ function, as evaluated by laboratory tests 7 days or more after the date when the anticancer drugs were given. When patients are recovering from myelosuppression, the revised criteria are shown in parentheses. White blood cell count≥3000/mm3 (2000/mm3) Platelet count≥10.0*104/mm3 (5.0*104/mm3) Aspartate aminotransferase≤100 IU/l Alanine aminotransferase≤100 IU/l Total bilirubin≤2.0 mg/dl Serum creatinine≤1.5 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify